TAVR

Transcatheter aortic valve replacement (TAVR) is a key structural heart procedure that has rapidly expanded in the decade since it was first FDA cleared. TAVR has come a paradigm shift in how many aortic stenosis patients are treated, now making up more than 50% of U.S. aortic valve replacements. It is less invasive than open heart surgery and recovery times are greatly reduced. TAVR can also be used in patients who otherwise are too high risk to undergo surgery. TAVR is referred to as transcatheter aortic valve implantation (TAVI) in many placed outside of the U.S. TAVR inspired the growing areas of transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

RSS icon
the words "FDA recall" on a board

FDA announces recall of nearly 8,000 Impella blood pumps due to risk of injury or death in TAVR patients

There have been 30 complaints so far about this issue, including 26 injuries and four deaths.

A transcatheter aortic valve replacement (TAVR) procedure being performed at Intermountain Healthcare. Image from Intermountain Healthcare

Atrial fibrillation after TAVR linked to much higher risk of death, heart failure

Researchers tracked data from nearly 7,000 TAVR patients for two years, focusing on all-cause mortality and heart failure hospitalizations.

Thumbnail

Permanent pacemakers after TAVR: Tracking the impact of modern self-expanding valves

Researchers explored data from more than 3,000 TAVR patients, presenting their results in JACC: Cardiovascular Interventions. 

doctor with overweight patient who may be treated with TAVR or surgery

TAVR vs. surgery among obese patients: What cardiologists need to know

Researchers tracked data from nearly 38,000 obese patients who underwent TAVR or SAVR, sharing their findings in a new meta-analysis. 

Thumbnail

Tracking patient outcomes after valve-in-valve TAVR, redo SAVR

It is becoming more and more important, researchers noted, to examine the lifetime management of patients who undergo aortic valve replacement.

Balloon expansion deployment of an Edwards Lifesciences Sapien 3 transcatheter aortic valve replacement (TAVR) device.

TAVR vs. surgery: Exploring 5-year outcomes among intermediate-risk patients

A group of renowned TAVR specialists examined data from 783 pairs of intermediate-risk patients, sharing their findings in the Journal of the American College of Cardiology.

No contrast transcatheter aortic valve replacement

New ‘zero-contrast’ TAVR technique shows promise in pilot study

Researchers think this new technique could be beneficial for patients presenting with both severe symptomatic aortic stenosis and chronic kidney disease. 

The Edwards Lifesciences Sapien transcatheter aortic valve replacement (TAVR) device in a heart model used to show patients how the device works.

Balloon-expandable valves deliver better short-term TAVR outcomes than self-expandable valves

A new meta-analysis, published in Frontiers in Cardiovascular Medicine, focused on data from nearly 3,000 patients with severe symptomatic aortic stenosis.

Displaying 177 - 184 of 419
Design by Adaptive Theme